dr liz mear, chief executive officer
DESCRIPTION
Dr Liz Mear, Chief Executive Officer. Innovation Health and Wealth. Innovation Health and Wealth was launched in December 2011 by the Prime Minister alongside the Life Sciences Strategy It is the NHS’s contribution to the Plan for Growth. What should be done to drive innovation?. - PowerPoint PPT PresentationTRANSCRIPT
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Dr Liz Mear, Chief Executive Officer
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Innovation Health and Wealth
Innovation Health and Wealth was launched in December 2011 by the Prime Minister alongside the Life Sciences Strategy
It is the NHS’s contribution to the Plan for GrowthWhy is innovation important to the
NHS?
What should be done to drive innovation?
1. Innovation transforms patient outcomes
2. Innovation can simultaneously improve quality and productivity
3. Innovation is good for economic growth
1. Reduce variation and increase compliance of NICE guidelines
2. Publish uptake metrics3. Establish a more systematic delivery
mechanism4. Align incentives and rewards5. Improve procurement6. Develop our people and hard wire
innovation into training7. Strength leadership in innovation8. Identify and mandate High Impact
Innovations
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Academic Health Science Networks
Academic Health Science Networks will:
• be a “systematic delivery mechanism for diffusion and collaboration”
• “align … clinical research, informatics, training and education and healthcare delivery”
• “improve patient and population health outcomes”
Innovation Health and Wealth says
Progress: •The NHS Chief Executive and the Chief Medical Officer designated 15 networks - go live during 2013/14 •Funding has been allocated and contracts are currently being signed
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Clarity of Purpose
Key Linkages and Leversthat enable the core purpose
of AHSNs to be delivered
Additional functionsthat locally the partners want to deliver through the AHSN
Core Purpose
Identification, adoption and spread of innovation and best practice
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Participation in AHSNs (1)
15 nationwide therefore importance of collaboration. Footprint 3-5 million alignment with other geographies, such as Clinical Senates, Strategic Clinical Networks and Health Education England is essential.
Funding from a ‘sunset review’ of other bodies
For the NHS opportunity to develop state-of-the art proven innovations and best practice in partnership, benefiting from the sharing of learning and expertise about innovation and best practice in an innovation network
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Participation in AHSNs (2)
For industry – helps creates the new relationship that is described in Innovation Health and Wealth and give a point of contact for the NHS
For higher education institutions – helps demonstrate impact of research as part of the life sciences agenda but the offer needs to be attractive and tangible
AHSNs will work together - to spread innovations and have a national voice
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
The licence
Five year licence from NHS England to the AHSN that would be:
An agreement between the members of the network and the NHS England that they will work together to improve patient care and population health; A “contract” to deliver defined tasks and outcomes for which network will receive funding from the NHS England, including local resources that the members will contribute.
AHSNs will be able to bid for other contracts and they may decide to work together to bid for contracts at a national level
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Four licence areas
• Identify and address unmet need• Speed up adoption of innovation• Identify and enable research• Create wealth
No ‘blueprint’
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Success
• Having a plan to build local partnerships across autonomous organisations
• Shared values• Strong working partnerships – commissioners and
providers (CCGs have a legal duty to promote innovation)
• Local leadership and energy for working across boundaries
• Clarity on operational delivery• National shared purpose across AHSNs• No duplication locally or nationally
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Challenges
• AHSNs give a simpler and supportive landscape but……• Central direction v local determination• Developing a culture of implementation across
boundaries• Developing collaboration across regions for the benefit
of residents• Developing whole pathway and whole system metrics
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
North West Coast AHSNImproving population health by reducing variation and equalising access to excellent care. Promoting a vibrant economy through investment, innovation and sustainability of employment.
Local priorities
•Cancer•Child/ Maternal Health•Cardiac Health•Stroke•Mental Health •Long Term Conditions
National lead areas
• Tele health/ care/ meds• Neurological conditions• Personalised medicines• Infection and tropical medicines
• Procurement
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Building up our national workstreams
School of Tropical Medicine/UCLAN
Neurological research
More Independent (Mi) draft document on working together
Personalised medicines – SBRI funding for personalised medicines for cardiac
Procurement – NHS England and the Innovation hub
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Building up our local workstreams
Child and maternal health – SBRI, LTSM, genomics
Cardiac – SBRI Neurological research
Stroke – Year of the Brain possibilities
Contribution to local system re-design
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Building up our links nationally and locally
Represented on the board for 3 million lives
on the NICE assessment panel
on the board of the Health Services Research Network
Building up links with Health e Research Centre (HERC) and big data companies
Contribution to Medilink events and newsletter
Presentation for R and D North West, CLRN chairs, national NHS/ Biopharmaceutical Forum
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Building our infrastructureThere should be Board providing leadership to the AHSN with an independent chair and an accountable officer – wide Board with multiple stakeholders and quarterly stakeholder forums
Executive team
• Gideon Ben-Tovim, Chair• Bruce Ash – Vice Chair• Liz Mear – Accountable Officer• Philip Dylak – Director of
Innovation, Nursing and AHPs• John Goodacre, Medical Director• Commercial Director - vacancy
Support staff
•Programme Managers•Project Managers•PR and Communications Manager•Funding and Grants Support Manager•Executive PA•Admin support
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Building up our relationship with local business
Commercial strategyIndustry groupMeet the experts x 4Medi-link eventsIndividual meetingsCRM databaseSBRI Neurological researchBig dataTender for industrial partner
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
National/ international projects
Stop and Go – European procurement project3 Million lives projectNICE assessmentEuropean Connected Healthcare AllianceNetwork of NetworksNorthern NetworkHorizon 2020International Festival of Business
Clinical Transition Programme - Presentation to David Nicholson – 12 January 2012
Before we next meet….
Academic SummitChild and Maternal Health SBRI competitionCommercial strategy finalised Posts advertisedPR improvedWebsite launched